Hospital groups are criticizing GlaxoSmithKline's new 340B contract pharmacy policy. PhRMA says it will keep pushing to change 340B.

Hospital Groups Pan GSK’s New 340B Contract Pharmacy Policy, PhRMA Says It Will Continue to Push for Reform

America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to the 340B program.

“It’s clear the pharmaceutical industry has little regard for making affordable drugs accessible to low-income patients, and GlaxoSmithKline is just the latest sad example of that,” said Beth Feldpush, America’s Essential Hospitals’ senior vice president of policy and advocacy. “This restriction will do nothing more than pad GSK’s bottom line at the expense—and maybe the lives—of our most underrepresented and underserved people.”

America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to the 340B program.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report